stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) EPS (diluted)
Erasca, Inc.'s EPS (diluted) for fiscal 2025 was −$0.44, compared with −$0.69 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$0.95. Over the past ten years it has ranged from −$4.83 (fiscal 2020) to −$0.10 (fiscal 2019); the current reading is higher than 86% of that period. EPS (diluted) has risen for 3 consecutive fiscal years. Erasca, Inc. ranks 199th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$0.44 | — |
| FY2024 | −$0.69 | — |
| FY2023 | −$0.83 | — |
| FY2022 | −$1.99 | — |
| FY2021 | −$1.85 | — |
| FY2020 | −$4.83 | — |
| FY2019 | −$0.10 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.14 | — |
| Mar 2026 | −$0.60 | — |
| Dec 2025 | −$0.10 | — |
| Sep 2025 | −$0.11 | — |
| 21 more quarters | Free account |
Against its own ten years
Low −$4.83
High −$0.10
Ten-year median
−$0.83
Current reading's percentile
86
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $8.19 |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$0.50 |
| ERAS Erasca, Inc. | −$0.95 |
| TVTX Travere Therapeutics, Inc. compare | −$1.29 |
| COGT Cogent Biosciences, Inc. compare | −$2.16 |
| DFTX Definium Therapeutics, Inc. compare | −$3.43 |
| DNTH Dianthus Therapeutics, Inc. compare | −$3.99 |
| CRSP CRISPR Therapeutics AG compare | −$4.74 |
| MANE Veradermics Incorporated compare | −$45.88 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item